Antibiotic-free plasmids
US-9217153-B2 · Dec 22, 2015 · US
US2016102332A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016102332-A1 |
| Application number | US-201514727017-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 1, 2015 |
| Priority date | Dec 3, 2012 |
| Publication date | Apr 14, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
We described novel methods for making targeted protein toxins by sortase-mediated protein ligation. The methods allow for a toxin and receptor-binding ligand to be ligated under mild conditions in vitro, following their expression and purification as single entities. The methods also provide a much more efficient way of making functional targeted fusion toxins compared to recombinant or chemical production of these structures.
Opening claim text (preview).
We claim: 1 . A method for making a protein toxin comprising a receptor-binding ligand, the method comprising the steps of: a. providing a protein toxin substrate and a C-terminal sortase-recognition motif optionally followed by an affinity epitope that is separated from the toxin by a linker; b. providing a targeting moiety comprising an N-terminal peptide; and c. contacting the protein toxin substrate of step (a) with the targeting moiety of step (b) with a sortase enzyme. 2 . The method of claim 1 , wherein the protein toxin substrate does not comprise its natural receptor binding domain or comprises a non-functional natural receptor binding domain. 3 . The method of claim 1 , wherein the targeting moiety is a receptor targeting ligand. 4 . The method of claim 1 , wherein the receptor is HER 2. 5 . The method of claim 3 , wherein the receptor targeting ligand is a HER2 antibody or HER2 AFFIBODY. 6 . The method of claim 1 , wherein the C-terminal sortase recognition motif is a sortase A recognition motif. 7 . The method of claim 6 , wherein the sortase A recognition motif is LPXTG (SEQ ID NO: 1), wherein X is any amino acid. 8 . The method of claim 7 , wherein the sortase A recognition motif is LPETGG (SEQ ID NO: 2). 9 . The method of claims 1 , wherein the C-terminal sortase recognition motif is a sortase B recognition motif. 10 . The method of claim 9 , wherein the sortase B recognition motif is NPQTN (SEQ ID NO: 3) or NPKTG (SEQ ID NO: 4). 11 . The method of claim 1 , wherein the affinity epitope is selected from a Histidine repeat (His 6 ) (SEQ ID NO: 5), maltose binding protein (MBP), protein A (ProtA), glutathione S-transferase (GST), calmodulin binding peptide (CBP), calmodulin, thioredoxin, Strep-tags, hemagglutinin, biotin, FLAG, V5, and c-myc. 12 . The method of claim 1 , wherein the linker comprises at least one Glycine-Serine repeat. 13 . The method of claim 12 , wherein the linker comprises 1-10 Glycine-Serine repeats (SEQ ID NO: 6). 14 . The method of claim 13 , wherein the linker comprises 3 or 4 Glycine-Serine repeats (SEQ ID NO: 7). 15 . The method of claim 1 , wherein the N-terminal peptide consists of more than two Glycine residues. 16 . The method of claim 15 , wherein the N-terminal peptide consists of 3-10 Glycine residues (SEQ ID NO: 8). 17 . The method of claim 16 , wherein the N-terminal peptide consists of five Glycine residues (SEQ ID NO: 9). 18 . The method of claim 1 , wherein the protein toxin is an anthrax toxin. 19 . The method of claim 1 , wherein the protein toxin is a diphtheria toxin. 20 . The method of claim 1 , further comprising the step of purifying the toxin that comprises a receptor-binding ligand. 21 . The method of claim 20 , wherein the step of purifying comprises sequential Ni 2+ -NTA affinity and size exclusion chromatography.
Preparation of peptides or proteins (single cell protein C12N1/00) · CPC title
Toxins · CPC title
containing a localisation/targetting motif · CPC title
containing a tag with affinity for a non-protein ligand · CPC title
containing a fusion with a toxin, e.g. diphteria toxin · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.